Rene Hoet

Prof. René Hoet, Chief Scientific Officer, brings to Imcheck Therapeutics over 20 years of experience as a leader in antibody discovery and development.

Before joining ImCheck, René spent 8 years at Bayer AG as Vice President Biologics Research, where his team was responsible for antibody lead discovery and optimization. Between 2008-2010, he was a member of the management team at Genmab and as Sr. Director Research led the team Product Related Research, Scientific Communication & Translational Research. Together with his team, he ran the antibody discovery programs and actively supported Genmab’s clinical antibody programs.

René started his industrial career at Target Quest (acquired by Dyax in 1999) where his last position was Vice President Research and Operational Manager of Dyax SA. He was the driving force for internal antibody lead discovery as well as external collaborations and supported the out-licensing of Dyax’ antibody phage libraries. From these libraries, 3 antibodies have been approved by the FDA & EMA and over 10 antibodies from varies companies are currently in clinical trials.

René Hoet is also Professor Biopharmaceutics at the University of Maastricht, Netherlands, guiding researchers to use antibodies to bridge the gap between academic research and pharmaceutical applications.

Rene Hoet is the Chief Scientific Officer at ImCheck Therapeutics, based in Europe. With a background in Biotechnology, Rene Hoet has a rich history of leadership and innovation.Rene Hoet studied Doctor's degree in philosophy Molecular immunology at Radboud University Nijmegen. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.